Aug 30, 2024

Featuring a slide presentation and related discussion from Dr Michiel van der Heijden, including the following topics:

• Efficacy and safety data from the Phase III EV-302/KEYNOTE-A39 trial comparing enfortumab vedotin/pembrolizumab to chemotherapy for patients with previously untreated metastatic urothelial bladder cancer (mUBC) (0:00)
• Principal findings from the Phase III CheckMate 901 substudy of nivolumab in combination with chemotherapy and continued as monotherapy compared to chemotherapy alone as first-line treatment for cisplatin-eligible patients with mUBC (14:36)
• Key data from the Phase III THOR trial of erdafitinib for patients with relapsed mUBC and susceptible FGFR3 or FGFR2 genetic alterations (22:03)
• Long-term findings with sacituzumab govitecan for patients with progressive mUBC; emerging data from the Phase III TROPiCS-04 study (29:43)
• Outcomes observed in the cohort of patients with mUBC in the Phase II DESTINY-PanTumor02 trial of trastuzumab deruxtecan (36:19)

CME information and select publications